Shield Diagnostics has signed an exclusive deal with Gemini Holdings which will allow them to develop Gemini's DNA based test for a gene that causes a predisposition to brittle-bone disease. Shield Diagnostics said the test could have other applications. The colourful banker, Mungo Parks, who masterminded Nomura International's attempt to 'own' the emerging pharmaceutical sector in the UK, has left the Japanese investment bank two years after he joined the firm. He used Nomura's resources to take large stakes in a number of biotechnology companies such as Xenova, Phytopharm and PPL, the company behind the cloning experiments that led to Dolly the sheep. Investments built up by Nomura in this sector total more than £50 million.
Sources and References
-
Shield's DNA deal
-
Nomura's colourful biotech king quits
Leave a Reply
You must be logged in to post a comment.